Xenon Pharmaceuticals stock gets 28,350 awards for new hires

Published on 10/06/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xenon Pharmaceuticals stock was last at USD 37.57 on October 5, 2026, while 17 analysts kept a Moderate Buy consensus. Q2 EPS beat estimates by USD 0.05.

XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals stock (ISIN CA98420N1050) was last at USD 37.57 on Nasdaq on October 5, 2026, down 1.18 percent from the prior close. The company announced 17,850 stock options and 10,500 restricted share units for eight new non-officer employees effective October 1, 2026, according to StockTitan on October 2, 2026.

Equity awards carry a USD 38.93 price

The options carry an exercise price of USD 38.93 per share, matching Xenon's share price on October 1, 2026. The options and restricted share units vest over four years, while each option has a 10-year term, making the announcement a recruitment measure with a potential dilution angle for existing holders.

The 28,350 awards compare with eight incoming employees, or 3,543.75 awards per recipient before distinguishing between options and restricted units. That structure gives the grant announcement a limited direct read-through for near-term earnings, but it adds a concrete equity cost to a company still funding late-stage development.

Q2 loss beats the consensus estimate

Xenon reported a second-quarter 2026 loss of USD 1.11 per share, compared with a consensus loss of USD 1.16 and a loss of USD 1.07 in the second quarter of 2025, according to MarketBeat in its October 3, 2026 report. The USD 0.05 beat against consensus was positive, although the year-over-year comparison still shows a wider per-share loss.

The company is developing azetukalner for epilepsy, major depressive disorder and bipolar depression. Its investor materials identify the molecule as a Phase 3 program, while the September 2026 pause in new psychiatry-trial enrollment remains an important risk for the broader development story.

Analyst targets remain above the share price

MarketBeat reported a Moderate Buy consensus from 17 analysts, including 13 Buy ratings, two Strong Buy ratings, one Hold and one Sell. The average 12-month target of USD 70.27 stands 86.9 percent above the USD 37.57 share price, showing a wide gap between published valuation expectations and the latest Nasdaq quote.

Analyst views are not uniform. Investing.com reported on September 18, 2026 that Deutsche Bank cut its target from USD 90.00 to USD 46.00 and downgraded Xenon from Buy to Hold after neuropsychiatric adverse events. That target is 22.4 percent above the latest share price, far below the broader consensus target.

Stock remains close to its yearly low

Xenon Pharmaceuticals stock was last at USD 37.57 on Nasdaq on October 5, 2026. The quote stood USD 1.50 above its 52-week low of USD 36.07 and below its 52-week high of USD 72.66, with market capitalization of USD 3.6 billion.